Paclitaxel
- PDF / 169,712 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 89 Downloads / 121 Views
1 S
Cystoid macular oedema: case report A 43-year-old woman developed cystoid macular oedema (CME) during treatment with paclitaxel for pancreatic cancer. The woman presented with decreased bilateral visual acuity for the last 3 months. Her medical history was significant for pancreatic cancer, for which she had been receiving chemotherapy with albumin-bound paclitaxel [Abraxane; dosage and route not stated] for the previous 7 months. A colour fundus photography and optical coherence tomography (OCT) imaging showed evidence of CME in both the eyes. Ultra-wide field (UWF) fluorescein angiography (FA) of the fovea showed minimal leakage in the right eye and no leakage in the left eye. UWF FA of the peripheral retina revealed no abnormal findings in either of the eyes, which indicated that there was no involvement of the peripheral retinal vessel in the development of CME. Indocyanine green angiography (ICGA) of the fovea revealed almost no leakage in either of the eyes. ICGA of the peripheral retina showed no abnormal findings. Based on the clinical presentation and results of the investigations, it was suspected that the CME was caused by paclitaxel. The woman’s therapy with paclitaxel was therefore discontinued, and the chemotherapy regimen was replaced by oxaliplatin and capecitabine. Two weeks after discontinuation of paclitaxel, an OCT image revealed disappearance of the CME. At the 3 months follow-up, an OCT image revealed no intra-retinal fluid in either of the eyes. Lee J, et al. Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema. Indian Journal of Ophthalmology 67: 2058-2059, No. 12, Dec 803504376 2019. Available from: URL: http://doi.org/10.4103/ijo.IJO_734_19
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
